Please visit answersincme.com/860/240201307-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aly-Khan A. Lalani, MD, FRCPC; Normand Blais, MD, MSc; and Dorothy Lo, MD, FRCP(C), MHSc, PhD. In this activity, experts in managing urothelial carcinoma and renal cell carcinoma (RCC) from across Canada discuss evidence-based strategies for integrating the latest systemic therapies into practice to optimize outcomes for patients with advanced urothelial carcinoma and resected/advanced RCC, with insights into regional practice considerations. Upon completion of this activity, participants should be better able to: Incorporate the latest evidence on frontline combination regimens into treatment planning for advanced urothelial carcinoma; Identify strategies to optimally incorporate adjuvant immunotherapy into treatment plans for eligible patients with early-stage renal cell carcinoma (RCC); and Evaluate how current evidence and guidelines may inform optimal sequencing of therapies in later-line settings for patients with advanced RCC.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Guidance on Menopause-Related Vasomotor Symptom Management: A Focus on Neurokinin-Targeted Treatment Options
From Evidence to Practice: Where Do BCMA Bispecific Antibodies and Anti-CD38 mAb Combinations Fit Into Community Care for RRMM?
Evolving Care in B-ALL: From Questions to Answers on the Role of CD19 Bispecific T-Cell Engagers
Management of High-Risk CLL in the BTK Inhibitor Era: Frontline to Double-Refractory Disease
Free AI-powered recaps of CME in Minutes: Education in Oncology & Hematology and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.